Content area

|
|

Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Forfatter(e)
Jann Mortensen & Liselotte Højgaard Klinik for Klinisk Fysiologi, Nuklearmedicin & PET, Diagnostisk Center Rigshospitalet Ugeskr Læger 2014;176:V04130224
Reference: 
Ugeskr Læger 2014;176:V04130224
Blad nummer: 
Sidetal: 
1399-1402
Radium-223 treatment of bone metastases from castration-resistant prostate cancer
The alpha emitter Radium-223 (223Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp­toms. Intravenously administered 223Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Gunvor Kramshøj Larsen | 04/08
28 kommentarer
af Jette Birgitte Lehnsbo Korsgaard | 03/08
2 kommentarer
af Olaf Bjarne Paulson | 03/08
1 Kommentar
af Søren Christian Jørgensen | 02/08
3 kommentarer
af Hanne Hulgaard | 02/08
4 kommentarer
af Christian Stefan Legind | 28/07
2 kommentarer
af Connie Lærkholm Hansen | 23/07
1 Kommentar
af Lene Heise Garvey | 23/07
4 kommentarer
af Peter Tagmose Thomsen | 20/07
1 Kommentar